ABthrax is a human monoclonal antibody drug that HGS discovered and developed for the treatment of inhalation anthrax. ABthrax represents a new way to address the anthrax threat. While antibiotics can kill the anthrax bacteria, they are not effective against the deadly toxins that the bacteria produce. ABthrax is a first-in-class treatment that targets anthrax toxins after they are released by the bacteria into the blood and tissues. In an inhalation anthrax attack, people may not know they are infected with anthrax until the toxins already are circulating in their blood, and it may be too late for antibiotics alone to be effective. At the end of January 2009, HGS began the delivery of 20,000 doses of ABthrax to the U.S. Strategic National Stockpile.

Click here for more information on ABthrax.